Condiciones de salud que aceite de pescado puede ayudar a apoyar.
Clinical and observational evidence suggests omega-3 PUFAs from fish oil may reduce anxiety symptoms, particularly when EPA predominates. A well-cited RCT in medical students found that omega-3 supplementation significantly reduced self-reported anxiety versus placebo. Mechanistically, omega-3s appear to modulate HPA-axis activation and inflammatory pathways implicated in anxiety. Evidence is promising but still limited by small sample sizes in individual trials.
Fish oil provides EPA and DHA—the most extensively studied omega-3 fatty acids for arterial health. Meta-analyses confirm fish oil reduces triglycerides by 25–30%, modestly lowers blood pressure, reduces platelet aggregation, and decreases arterial inflammation. The 2025 PubMed review explicitly lists fish oil among nutraceuticals with favorable arterial vascular effects.
Fish oil provides EPA and DHA omega-3 fatty acids that reduce synovial inflammation by suppressing prostaglandins, leukotrienes, and pro-inflammatory cytokines. Meta-analyses confirm benefits for rheumatoid arthritis (reduced joint pain, morning stiffness, NSAID use), and narrative reviews support a role in osteoarthritis management.
Fish oil, rich in EPA and DHA, reduces pro-inflammatory leukotriene synthesis relevant to asthmatic airway inflammation. Clinical trials, including pediatric studies, have examined fish oil supplementation for asthma, with AHRQ evidence reviews noting its potential role. A clinical trial (NCT06560255) is examining fish oil in pregnancy for prevention of early childhood asthma in a large RCT.
Fish oil omega-3s have documented effects on exercise recovery, particularly reducing delayed-onset muscle soreness (DOMS) in untrained individuals. A systematic review of 32 RCTs in athletes found consistent effects for fish oil on skeletal muscle recovery, cardiovascular dynamics in cyclists, and post-exercise nitric oxide responses. Effects on primary performance metrics (endurance, maximal strength) are not clearly established.
Children and adults with ADHD consistently show lower blood EPA and DHA levels than neurotypical controls. Multiple RCTs and meta-analyses have examined omega-3 supplementation for ADHD symptoms, with EPA showing the most consistent, modest positive effects on hyperactivity, inattention, and impulsivity. Fish oil omega-3s are considered a safe adjunct, not a replacement for first-line ADHD treatments.
Fish oil, providing EPA and DHA, is one of the most studied natural supplements in autoimmune disease. Clinical trials across RA (16/20 showing benefit) and SLE (6/9 showing benefit) support its use as adjunctive therapy. Mechanisms include modulation of eicosanoid synthesis and suppression of pro-inflammatory cytokines.
Fish oil, as the primary dietary source of EPA and DHA, has RCT evidence for reducing low back pain. A 3-month RCT (n=36; 15 mL fish oil daily) found marked LBP reduction. A clinical trial (NCT02774109) studied 3000 mg/day fish oil with EPA and DHA for 8 weeks in chronic nonspecific LBP, and a 2006 Surgical Neurology study found reduced pain and NSAID use in neck/back pain patients after fish oil supplementation.
Fish oil (EPA and DHA) has well-recognized antiplatelet effects documented in multiple RCTs. EPA and DHA are incorporated into platelet membranes, altering fluidity and reducing TXA2 production and platelet aggregation. A 2024 systematic review of 11 RCTs (n=120,643) confirmed antiplatelet activity without significant overall bleeding risk increase at standard doses.
Fish oil is the primary dietary source of EPA and DHA omega-3 fatty acids, and among the most extensively studied nutraceuticals for blood pressure. Multiple large meta-analyses of RCTs confirm significant SBP and DBP reductions. Both AHA and NIH ODS formally recognize fish oil's antihypertensive effects.
Fish oil primarily lowers serum triglycerides in people with type 2 diabetes, with modest or inconsistent direct effects on fasting blood glucose or HbA1c. A meta-analysis of 45 RCTs in >2,600 T2DM patients found omega-3 supplementation associated with significant reductions in triglycerides and HbA1c. Fish oil may improve insulin sensitivity partly through anti-inflammatory mechanisms acting on PPAR-γ expression.
Fish oil provides concentrated EPA and DHA omega-3 fatty acids with anti-inflammatory effects on joint tissues. The Arthritis Foundation recognizes fish oil as having potential to reduce joint inflammation. Podiatric specialists recommend omega-3s from fish oil for big toe joint and bunion pain management. A dietary approach including fatty fish (omega-3 source) is recommended by the Bunion Institute for managing bunion-related inflammation.
Fish oil (omega-3 fatty acids EPA and DHA) is explicitly cited by ADAM and Healthgrades for bursitis. It reduces the production of pro-inflammatory eicosanoids over time. Evidence is mixed for acute inflammation but consistent for reducing inflammatory chemical production. Multiple authoritative bursitis references include it as a recommended supplement.
Fish oil providing EPA and DHA is explicitly listed in a PMC peer-reviewed cellulite review (2023) among oral supplements used for cellulite due to antioxidant and anti-inflammatory effects. Omega-3 fatty acids reduce adipose tissue inflammation, improve microvascular endothelial function, and mechanistically address the inflammatory and vascular pathology of cellulite.
Fish oil (EPA and DHA) is primarily established as a triglyceride-lowering agent, reducing TG by 20–50% at 2–4 g/day. It also modestly reduces total cholesterol and non-HDL-C. FDA-approved prescription omega-3 formulations are indicated for severe hypertriglyceridemia and are part of standard dyslipidemia management.
Fish oil, rich in the omega-3 fatty acids EPA and DHA, has robust clinical and mechanistic evidence supporting a role in reducing chronic inflammation. Multiple RCTs and meta-analyses show reductions in inflammatory biomarkers such as CRP, and clinical benefits have been demonstrated most consistently in rheumatoid arthritis. Evidence in other inflammatory conditions (IBD, asthma) is more mixed. Effects appear dose-dependent and are most pronounced in populations with elevated baseline inflammation.
Fish oil provides EPA and DHA omega-3 fatty acids that reduce pro-inflammatory eicosanoid synthesis and generate pro-resolving mediators. A 2025 systematic review/meta-analysis found omega-3 supplementation produces a moderate, significant reduction in chronic pain intensity. A clinical study found ~59% of patients with disc disease could replace NSAIDs with fish oil.
Observational evidence consistently links higher omega-3 status with lower risk of cognitive decline and dementia. DHA is a critical structural component of synaptic membranes, and fish oil may delay brain atrophy in aging. RCT evidence in cognitively healthy older adults has been largely neutral for preventing decline; benefits are more apparent in those with existing MCI or low baseline omega-3 status.
Fish oil (omega-3 fatty acids) has been evaluated in multiple RCTs and two Cochrane reviews for ulcerative colitis. While individual small trials show anti-inflammatory benefit and reduced steroid requirements, Cochrane reviews found insufficient definitive evidence for maintenance of remission. Fish oil reduces leukotriene B4 and pro-inflammatory eicosanoid production in colonic mucosa.
Fish oil (omega-3 fatty acids EPA and DHA) has been extensively studied in Crohn's disease. A 1996 NEJM RCT found enteric-coated fish oil reduced CD relapse; however, the 2008 JAMA EPIC trials (two large RCTs) found no significant benefit for remission maintenance. A Cochrane review confirmed no consistent benefit. Fish oil is still included in CD nutritional management for anti-inflammatory support.
Omega-3 fatty acids from fish oil are among the most studied nutritional interventions for depression. Multiple meta-analyses of RCTs support a clinically meaningful antidepressant effect, particularly for EPA-dominant formulations (≥60% EPA) at doses ≥1 g/day. Epidemiological data consistently show an inverse relationship between fish consumption and depression prevalence across countries. Evidence is strongest for MDD treatment rather than prevention.
Fish oil (containing EPA and DHA) has been studied in multiple RCTs for atopic dermatitis, showing modest but inconsistent improvements in pruritus and affected surface area. The AAD and NCCIH note inconsistent evidence. Anti-inflammatory mechanisms via eicosanoid modulation are well-established.
Fish oil (as a source of EPA and DHA) is specifically recommended by authoritative medical evidence-based resources for diverticulitis at 1,000 mg one to two times per day. Multiple university-associated medical center protocols and evidence-based databases endorse fish oil supplementation for its anti-inflammatory activity in diverticular disease.
Fish oil EPA and DHA modulate tear film quality through anti-inflammatory and specialized pro-resolving mediator (resolvin, protectin) pathways. Multiple RCTs and the large DREAM extension study have evaluated omega-3 for dry eye disease. A 2025 RCT in Sjögren's syndrome patients found significantly lower dry eye symptom scores with omega-3 versus placebo.
Omega-3 PUFAs from fish oil are structural components of the skin's lipid barrier and modulate cutaneous inflammation. Clinical evidence shows fish oil supplementation improves skin moisturization and reduces pruritus in conditions associated with dry skin. A prospective cohort study in hemodialysis patients (n=31) found 1,000 mg/day fish oil for 3 months significantly improved skin moisture and reduced inflammatory pruritus.
Fish oil, rich in EPA and DHA (omega-3 fatty acids), has anti-inflammatory effects relevant to eczema via modulation of eicosanoid production and Th2 inflammatory pathways. RCTs and systematic reviews have assessed fish oil in atopic dermatitis, with some trials showing reductions in eczema severity, though overall results are mixed.
DHA is a major structural component of sperm membranes (~25–35% of total sperm phospholipid fatty acids) and is essential for acrosome formation, sperm motility, and morphology. A 2018 systematic review and meta-analysis found omega-3 supplementation significantly improved sperm concentration and total motility versus controls. A JAMA Network Open study linked fish oil supplementation with improved reproductive hormone levels and semen quality in men.
Omega-3 fatty acids from fish oil may improve female fertility outcomes including egg quality, embryo morphology, endometrial receptivity, and IVF success rates. A 2024 meta-analysis of 13 studies involving over 4,000 women found omega-3 intake was associated with higher fertilization and pregnancy rates in both natural conception and ART contexts.
Fish oil provides EPA and DHA omega-3 fatty acids that reduce synovial inflammation by modulating prostaglandin and leukotriene biosynthesis. Clinical evidence supports reductions in morning stiffness and joint tenderness, particularly in rheumatoid arthritis. Fish oil is one of the most studied nutritional supplements with hundreds of clinical trials examining its anti-inflammatory role in joint tissue.
Children with ADHD consistently show lower blood levels of long-chain PUFAs including EPA and DHA compared to neurotypical controls. Multiple RCTs have assessed fish oil supplementation in children with ADHD, with mixed but directionally positive results for attention and hyperactivity. Evidence is strongest as an adjunct to standard therapies rather than monotherapy.
DHA is a major structural component of the retinal photoreceptor cell membrane, and adequate omega-3 status is essential for optimal visual development and retinal function. Fish oil supplementation supports eye health through anti-inflammatory EPA/DHA pathways and retinal DHA incorporation. Observational and mechanistic evidence supports fish oil's role in general retinal and ocular surface health.
Omega-3 supplementation as an adjunct to non-surgical periodontal therapy has been shown in RCTs to significantly improve clinical attachment loss and probing depth in periodontitis patients. Fish oil's anti-inflammatory EPA and DHA reduce pro-inflammatory eicosanoids driving periodontal tissue destruction. ConsumerLab notes emerging clinical evidence that post-'deep cleaning' fish oil reduces bleeding and pocketing in severe gum disease.
Fish oil, as the primary dietary source of EPA and DHA, has been studied in multiple clinical trials for migraine prevention. Clinical trials show significant reductions in migraine days, attack frequency, and severity with high-dose EPA fish oil supplementation. It reduces neuroinflammatory mediators implicated in migraine pathogenesis.
Fish oil is the primary dietary source of EPA and DHA omega-3 fatty acids with extensive clinical evidence for healthy aging, including reduced biological aging pace on DNA methylation clocks (VITAL trial follow-up, 2023), reduced telomere shortening, and cardiovascular/cognitive protection in aging adults.
DHA and EPA from fish oil are critical for fetal and infant brain, retina, and nervous system development. Multiple studies confirm that maternal fish oil supplementation during pregnancy and lactation benefits infant neurodevelopment, visual acuity, and cognitive outcomes. The NIH ODS explicitly identifies infant health and neurodevelopment as a key domain for omega-3 research.
Fish oil omega-3s are one of the most extensively studied dietary supplements for cardiovascular health. Their most robust and FDA-recognized effect is triglyceride reduction (dose-dependent, up to 30–45% at high doses). Large RCTs including REDUCE-IT (icosapentaenoic acid) demonstrate significant reductions in major adverse cardiovascular events (MACE) in high-risk populations. Effects on reducing overall CVD mortality have been inconsistent across trials.
Fish oil has complex and partially conflicting evidence regarding cardiac arrhythmias. Mechanistically, EPA and DHA stabilize cardiac ion channels and have anti-arrhythmic properties demonstrated in animal models and early human studies. However, large RCTs have not confirmed a reduction in atrial fibrillation risk, and high-dose fish oil supplements may paradoxically increase AF risk in some populations.
Fish oil, as a source of EPA and DHA, has been studied in multiple clinical trials for both UC and CD, and is among the most commonly used CAM supplements by IBD patients. It reduces mucosal LTB4 and prostaglandin E2 levels and has demonstrated benefit in CD relapse prevention in clinical trials.
Fish oil omega-3s may improve insulin sensitivity through anti-inflammatory mechanisms, including upregulation of PPAR-γ expression and downregulation of TNF-α and IL-1—cytokines that impair insulin signaling. Several RCTs in T2DM and gestational diabetes patients demonstrate improvements in HOMA-IR and related parameters, though direct fasting glucose effects are modest.
Fish oil, rich in EPA and DHA omega-3 PUFAs, has documented effects on intestinal tight junction integrity and barrier restoration. A PMC-indexed animal study (PMC3117781) showed fish oil administration ameliorated disruption of epithelial integrity by improving tight junction morphology and function. The LIBRE RCT confirmed n-3 PUFAs improve intestinal barrier integrity, and multiple GI clinical reviews support fish oil for gut barrier health.
Observational evidence consistently shows that people with higher fish and omega-3 intake are less likely to develop age-related macular degeneration (AMD). A systematic meta-analysis found high dietary omega-3 intake associated with a 38% lower risk of developing both early and late AMD. DHA constitutes a major fraction of retinal photoreceptor membrane phospholipids, making omega-3 status mechanistically critical to retinal health.
DHA is a critical structural component of neuronal membranes and synapses, supporting the mechanistic rationale for fish oil's role in memory. Clinical trial evidence in cognitively healthy older adults has been largely negative for memory enhancement; however, observational evidence links higher omega-3 status with better memory performance, especially in populations with low baseline omega-3 levels.
Fish oil supplementation has shown clinically meaningful reductions in primary dysmenorrhea (menstrual cramp) severity in multiple RCTs. The mechanism involves EPA and DHA competing with arachidonic acid to reduce pro-inflammatory prostaglandin E2 and prostaglandin F2α synthesis in the uterus, which are the primary mediators of menstrual pain.
Fish oil, via its EPA and DHA content, has substantial clinical and epidemiological evidence supporting a role in addressing key components of metabolic syndrome (MetS), particularly elevated triglycerides and high blood pressure. Multiple RCTs and meta-analyses confirm significant triglyceride-lowering and modest antihypertensive effects in MetS patients. Effects on HDL cholesterol, fasting glucose, and waist circumference are less consistent. Overall evidence is graded as clinically meaningful but not uniformly positive across all MetS criteria.
Fish oil omega-3s have been studied for attenuation of exercise-induced muscle damage, particularly DOMS reduction in untrained individuals. EPA and DHA incorporate into skeletal muscle cell membranes, maintain membrane integrity during eccentric loading, and generate pro-resolving mediators that accelerate inflammation resolution. Evidence for DOMS reduction is directionally positive; effects on strength or performance recovery are less consistent.
EPA and DHA from fish oil are essential structural and functional components of neuronal cell membranes throughout the central and peripheral nervous system. DHA is highly concentrated in neuronal synapses, myelin sheaths, and the brain gray matter, supporting neurotransmission, myelination, and neuroprotection. Deficiency is associated with neurological impairments across the lifespan.
Fish oil omega-3s have been studied for peripheral neuropathy, particularly diabetic peripheral neuropathy. EPA and DHA support neuronal membrane integrity, reduce neuroinflammation, and promote nerve growth factor (NGF) expression. Clinical trials in diabetic patients show improvements in nerve conduction velocity and reduction in neuropathic pain symptoms with omega-3 supplementation.
Multiple clinical trials and meta-analyses support omega-3 supplementation from fish oil for women with polycystic ovary syndrome (PCOS). Fish oil has been shown to reduce androgen levels, improve menstrual frequency, lower triglycerides, and reduce insulin resistance—all key PCOS features. The ConsumerLab Fish Oil Review notes a recent study showing fish oil may improve pregnancy rates in PCOS-related infertility.
DHA levels in mothers deplete significantly during pregnancy as the fetus draws on maternal reserves, and low postpartum omega-3 status is associated with greater risk of postpartum depression. Fish oil supplementation postnatally supports maternal mood, with DHA passing through breast milk to support continued infant brain development. Cross-national data link DHA content in breast milk with lower rates of postpartum depression.
Fish oil is the most-studied source of prenatal omega-3 DHA and EPA. A Cochrane meta-analysis of 70 RCTs involving 19,927 pregnant women found omega-3 (fish oil) supplementation reduced preterm births before 34 weeks by 42% and reduced low birthweight. ACOG recommends 250–375 mg EPA+DHA per day during pregnancy, with fish oil supplements as the primary alternative for women with limited seafood intake.
Fish oil supplementation for psoriasis has been evaluated in over 13 RCTs. A meta-analysis of 10 studies involving 560 participants found a significant reduction in PASI score (−1.58; 95% CI: −2.24, −0.92; p<0.001) in favor of omega-3 supplementation. Results across trials are mixed, with some showing meaningful clinical improvement and others showing no benefit.
Fish oil, as the primary source of EPA and DHA omega-3 fatty acids, is cited in naturopathic urticaria protocols for its anti-inflammatory properties. It is recommended in home remedy and integrative medicine sources for reducing hives. The mechanistic basis is competitive inhibition of pro-inflammatory arachidonic acid pathways relevant to mast cell-driven urticaria.
Fish oil, rich in EPA and DHA, is the most extensively studied natural supplement for RA. At least 12 placebo-controlled double-blind RCTs document clinical improvements including reduced morning stiffness, tender joints, and NSAID requirements. A 2017 systematic review of 22 marine oil trials found moderate-quality evidence for benefit in RA.
Fish oil omega-3s have been investigated for seasonal affective disorder (SAD) given the established links between omega-3 status, mood regulation, serotonin metabolism, and inflammatory pathways implicated in depressive disorders. Population-level data show higher fish consumption correlates with lower rates of depression including seasonal forms. While specific SAD RCTs are limited, the broader antidepressant evidence base supports seasonal mood applications.
Fish oil omega-3s modulate skin inflammatory pathways, protect against photoaging, and may support dermal collagen preservation. EPA has been shown to inhibit UV-induced matrix metalloproteinase (MMP) production that degrades collagen. Clinical and in vitro evidence supports a role for fish oil in attenuating photoaging mechanisms and maintaining skin structural integrity.
Fish oil (EPA+DHA) is one of the most robustly studied supplements for triglyceride reduction. Multiple meta-analyses and large RCTs confirm it can lower fasting triglycerides by 20–50% at therapeutic doses (≥2–4 g EPA+DHA/day). The American Heart Association recognizes its efficacy. The FDA has approved prescription omega-3 formulations for hypertriglyceridemia.
Volver